BIIB250117C167500
- 0.00
- 0.000.00%
Biogen Newsroom
Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $255
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating
Biogen Announces New Chief Accounting Officer Appointment
BMO Capital Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $164
Biogen's Hold Rating: Navigating Challenges in Alzheimer's Treatments and Pipeline Development
The CEO of Bojian stated that there is no need to seek additional trades to develop the business.
On January 15, at the JPMorgan annual Medical Care conference, Biogen's CEO Chris Viehbacher stated that by 2028, revenue from new products is expected to exceed current sales, and there is no need to seek additional Trades for Business development. Viehbacher explained that the Analyst community's perspective is that Biogen's future depends on our next Trade, which the company internally does not agree with. Last Friday, Biogen proposed to acquire its marketing partner Sage Therapeutics for its postpartum depression treatment.
Biogen CEO Sees No Burning Need for More Acquisitions
Sarepta, Biogen Drugs With Accelerated Approval Under Fire in FDA Report
Biogen Stock at Lowest Level Since February 2013 Following J.P. Morgan Presentation
10 Health Care Stocks With Whale Alerts In Today's Session
Biogen Stock Touches 52-week Low at $144.96 Amid Challenges
Biogen Bid for Sage Does Not Change Narrative, Says BMO Capital
Digital Neuro Biomarkers Market Research 2025-2030, Competitive Analysis of Altoida, Koneksa, Biogen, Roche, NeuraMetrix, Merck, Linus Health, Neurotrack Technologies, Huma, and NeuraLight
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Sage Therapeutics Seen Shunning Biogen Bid -- Market Talk
Biogen, Eisai Say Injectable Alzheimer's Therapy Granted FDA Review
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
Wells Fargo & Co has lowered the Target Price for Bausch Health to $165.
Gelonghui, January 14 | Wells Fargo & Co: Lowered the Target Price for Hovione from $190 to $165, maintaining a "Hold" rating. (Gelonghui)
Reported Earlier, Eisai And Biogen Announced FDA Acceptance Of LEQEMBI BLA For Weekly Subcutaneous Dosing To Treat Early Alzheimer's Disease
Express News | FDA Accepts Leqembi® (Lecanemab-Irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease